Table 3 Risk factors for HCC in PS matched cohort.

From: Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B

 

Univariate analysis

Multivariate analysis

HR

95% CI

P-value

HR

95% CI

P-value

Main model

Tenofovir (ref: Entecavir)

0.82

0.64

1.04

0.102

0.83

0.65

1.06

0.129

Age, y/o

1.05

1.04

1.06

< 0.001

1.04

1.03

1.05

< 0.001

Male (ref: female)

1.95

1.48

2.58

< 0.001

1.90

1.43

2.51

< 0.001

Liver cirrhosis (ref: without)

4.07

3.11

5.31

< 0.001

3.20

2.43

4.20

< 0.001

DM (ref: without)

1.63

1.26

2.10

< 0.001

1.19

0.92

1.54

0.192

Covariates

Plateleta

0.990

0.988

0.992

< 0.001

0.994

0.992

0.996

< 0.001

AFPa

0.999

0.998

1.001

0.448

0.999

0.997

1.001

0.222

Albumina

0.60

0.51

0.70

< 0.001

0.77

0.65

0.91

0.002

Bilirubina

0.99

0.96

1.02

0.488

0.96

0.92

0.99

0.488

INRa

1.57

1.16

2.14

0.004

1.04

0.68

1.59

0.854

FIB-4a

1.04

1.03

1.05

< 0.001

1.02

1.01

1.04

0.012

APRIa

1.01

1.00

1.02

0.204

0.99

0.98

1.01

0.407

Prior NAa (ref: no use)

0.96

0.70

1.31

0.782

0.87

0.63

1.19

0.388

  1. PS propensity score, HR hazard ratio, CT confidence interval, DM diabetes mellitus, AFP alpha-fetoprotein, INR international normalized ratio, FIB-4 fibrosis index based on 4 factors, APRI AST to platelet ratio index, NA nucleos(t)ide analogue.
  2. aAdjusted for tenofovir, sex, age, liver cirrhosis, DM.
Back to article page